Adagrasib Clinical Trials
8 recruitingDrug
Phase 25Phase 13Phase 32
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 2
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma
City of Hope Medical Center535 enrolled13 locationsNCT07288034
Recruiting
Phase 1
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Solid Tumors With HRAS Alterations
Kura Oncology, Inc.300 enrolled40 locationsNCT06026410
Recruiting
Phase 2
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Ryan Gentzler, MD30 enrolled3 locationsNCT06248606
Recruiting
Phase 1
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Advanced Solid TumorNon-small Cell Lung Cancers
M.D. Anderson Cancer Center52 enrolled1 locationNCT06130254
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 1Phase 2
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Metastatic Colorectal CancerKRAS G12C Mutations
M.D. Anderson Cancer Center31 enrolled2 locationsNCT06412198
Recruiting
Phase 2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Metastatic CancerAdvanced CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc.200 enrolled120 locationsNCT05853575